Ravulizumab Outcomes in Polish Patients With aHUS
← catalyst calendarNCT07399730 · readout in 1,138 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
80estimated
Sites
10
Country
Poland
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-24 | actual | When the study began enrolling |
| Primary completion | 2029-09-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-18 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atypical Hemolytic Uremic Syndrome
Intervention
- Drug: Ravulizumab
Primary outcomes
what the primary-completion date above is the date OFProportion of patient attaining Complete Thrombotic Microangiopathy (TMA) Response during observation (naïve)
measured Up to 24 months
Proportion of patients attaining/maintaining. Complete TMA Response during observation (switched)
measured Up to 24 months
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed